Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial
Wirksamkeit und Risiken von Dapagliflozin bei der Behandlung der metabolisch-dysfunktionassoziierten steatotischen Lebererkrankung mit Typ-2-Diabetes: randomisierte kontrollierte Studie
Frontiers in Medicine · 25.03.2025 · 12
DOI: 10.3389/fmed.2025.1542741 ↗Auf einen Blick
Bei 24 Patient:innen mit MASLD und Typ-2-Diabetes senkte Dapagliflozin einige Stoffwechselparameter zusätzlich, bei ähnlicher Abnahme von AST und ALT in beiden Gruppen. Zugleich nahm der Skelettmuskelindex ab.
Fragestellung
Wie wirksam und wie risikoreich ist Dapagliflozin im Vergleich zu Vitamin E bei MASLD mit Typ-2-Diabetes?
Methode
Prospektive randomisierte kontrollierte Studie; 24 Patient:innen erhielten 24 Wochen Dapagliflozin 5 mg/Tag oder Vitamin E 150 mg/Tag.
Ergebnisse
Beide Gruppen zeigten signifikante Abnahmen von AST und ALT ohne signifikante Gruppenunterschiede. Unter Dapagliflozin sanken BMI, HbA1c, γ-GT, Ferritin, LDL-Cholesterin, Körperfett und der Skelettmuskelindex signifikant.
Schlussfolgerung der Autor:innen
Dapagliflozin zeigte mehrere metabolische Vorteile bei MASLD mit Typ-2-Diabetes, die Abnahme der Muskelmasse weist jedoch auf einen möglichen nachteiligen Effekt auf Langzeitergebnisse hin.
Kernaussagen
- AST und ALT nahmen in beiden Gruppen signifikant ab
- Unter Dapagliflozin verbesserten sich mehrere Stoffwechselparameter
- Der Skelettmuskelindex nahm unter Dapagliflozin signifikant ab
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Medicine, online erschienen am 25.03.2025. Verfasst von Hiroo Fukada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Pharmacotherapy for metabolic dysfunction-associated steatotic liver disease (MASLD) is still under development and has not been fully established. For patients with MASLD and type 2 diabetes, treatment with antidiabetic drugs, including sodium–glucose cotransporter 2 (SGLT2) inhibitors, is recommended, with vitamin E supplementation when treatment efficacy is insufficient. The benefits and risks of SGLT2 inhibitors for MASLD with type 2 diabetes have not been thoroughly investigated.
Objective
This prospective randomized controlled trial aimed to elucidate the effectiveness and risks of the SGLT2 inhibitor dapagliflozin in comparison with vitamin E in patients with MASLD and comorbid type 2 diabetes.
Methods
The trial enrolled 24 patients with MASLD and comorbid type 2 diabetes, who were assigned to receive either dapagliflozin (5 mg/day) or vitamin E (150 mg/day) for 24 weeks. The primary outcomes included serum levels of AST, ALT, γ-GT, and type IV collagen, and the FIB-4 index. The secondary outcomes were BMI, HbA1c and serum ferritin levels, lipid profile, body composition assessed using InBody, and hepatic fat content and fibrosis evaluated with FibroScan. Adverse events were monitored throughout the study period.
Results
Both groups demonstrated significant reductions in serum AST and ALT levels but intergroup differences were not significant. The dapagliflozin group showed additional benefits, with significant decreases in BMI and HbA1c, γ-GT, ferritin, LDL cholesterol, and body fat levels, indicating improved glycemic control and lipid profile. Dapagliflozin administration was associated with a significant decline in the skeletal muscle index, indicating a risk of muscle loss absent in the vitamin E group. This reduction in muscle mass is clinically significant as it suggests a potential risk of worsened overall survival with dapagliflozin treatment.
Conclusion
This study indicates that dapagliflozin provides several metabolic benefits in patients with MASLD and comorbid type 2 diabetes, including reductions in the levels of liver enzymes and body fat, but the observed decrease in muscle mass suggests a potential adverse effect on long-term survival outcomes. Muscle mass should be monitored in patients receiving dapagliflozin therapy to mitigate the risk of sarcopenia progression and ensure a comprehensive approach to MASLD management. Clinical trial registration https://jrct.niph.go.jp/re/reports/detail/81182 , identifier jRCT1031180386.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
- Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan.
- Department of Internal Medicine, Tokyo Metropolitan Tobu Chiiki Hospital, Tokyo, Japan.
- Technology Innovation Center, Juntendo University, Tokyo, Japan.
Zitieren
APA
Fukada, H., Kon, K., Yaginuma, R., Uchiyama, A., Morinaga, M., Ishizuka, K., Fukuhara, K., Okubo, H., Suzuki, S., Nojiri, S., Yamashina, S., & Ikejima, K. (2025). Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1542741
Vancouver
Fukada H, Kon K, Yaginuma R, Uchiyama A, Morinaga M, Ishizuka K, et al. Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial. Frontiers in Medicine. 2025;12. doi:10.3389/fmed.2025.1542741
BibTeX
@article{Fukada2025,
author = {Fukada, Hiroo and Kon, Kazuyoshi and Yaginuma, Reiko and Uchiyama, Akira and Morinaga, Maki and Ishizuka, Kei and Fukuhara, Kyoko and Okubo, Hironao and Suzuki, Satoko and Nojiri, Shuko and Yamashina, Shunhei and Ikejima, Kenichi},
title = {Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial},
journal = {Frontiers in Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fmed.2025.1542741}
}
EUVIMED